Literature DB >> 24106727

Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics.

Shane M Devlin, Brian Bressler, Charles N Bernstein, Richard N Fedorak, Alain Bitton, Harminder Singh, Brian G Feagan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24106727      PMCID： PMC3805336          DOI： 10.1155/2013/327120

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN： 0835-7900            Impact factor:   3.522


× No keyword cloud information.
  24 in total

Review 1.  Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins.

Authors:  Christian Combe; Roger L Tredree; Huub Schellekens
Journal:  Pharmacotherapy       Date:  2005-07       Impact factor: 4.705

2.  Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.

Authors:  Severine Vermeire; Maja Noman; Gert Van Assche; Filip Baert; Geert D'Haens; Paul Rutgeerts
Journal:  Gut       Date:  2007-01-17       Impact factor: 23.059

Review 3.  The first subsequent entry biologic authorized for market in Canada: the story of Omnitrope, a recombinant human growth hormone.

Authors:  Agnes V Klein
Journal:  Biologicals       Date:  2011-07-23       Impact factor: 1.856

Review 4.  Subsequent entry biologics/biosimilars: a viewpoint from Canada.

Authors:  Anthony S Russell; Vandana Ahluwalla; Cheryl Barnabe; Shahin Jamal; Robert C Offer; Wojciech P Olszynski; Kam Shojania; Boulos Haraoui
Journal:  Clin Rheumatol       Date:  2012-08-26       Impact factor: 2.980

5.  Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012.

Authors:  Jonathan Kay; Brian G Feagan; Micheal S Guirguis; Edward C Keystone; Agnes V Klein; Anthony S Lubiniecki; Diane R Mould; Kwasi A Nyarko; Anthony A G Ridgway; Maureen E Trudeau; Jian Wang
Journal:  Biologicals       Date:  2012-10-17       Impact factor: 1.856

6.  Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin.

Authors:  V Skibeli; G Nissen-Lie; P Torjesen
Journal:  Blood       Date:  2001-12-15       Impact factor: 22.113

7.  Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties.

Authors:  P L Storring; R J Tiplady; R E Gaines Das; B E Stenning; A Lamikanra; B Rafferty; J Lee
Journal:  Br J Haematol       Date:  1998-01       Impact factor: 6.998

8.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

Authors:  Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2003-02-13       Impact factor: 91.245

9.  Biosimilars: a regulatory perspective from America.

Authors:  Jonathan Kay
Journal:  Arthritis Res Ther       Date:  2011-05-12       Impact factor: 5.156

10.  A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.

Authors:  Dae Hyun Yoo; Pawel Hrycaj; Pedro Miranda; Edgar Ramiterre; Mariusz Piotrowski; Sergii Shevchuk; Volodymyr Kovalenko; Nenad Prodanovic; Mauricio Abello-Banfi; Sergio Gutierrez-Ureña; Luis Morales-Olazabal; Michael Tee; Renato Jimenez; Omid Zamani; Sang Joon Lee; HoUng Kim; Won Park; Ulf Müller-Ladner
Journal:  Ann Rheum Dis       Date:  2013-05-16       Impact factor: 19.103
View more
  6 in total

1.  Subsequent entry biologics - opportunities and challenges.

Authors:  Subrata Ghosh
Journal:  Can J Gastroenterol       Date:  2013-10       Impact factor: 3.522

2.  Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists.

Authors:  David Grabowski; Bradley Henderson; Dennis Lam; Edward C Keystone; Carter Thorne; Shahin Jamal; Janet Pope; Boulos Haraoui; Daming Lin; Leigh Revers
Journal:  Clin Rheumatol       Date:  2015-01-15       Impact factor: 2.980

3.  The Role of Biosimilars in Inflammatory Bowel Disease.

Authors:  Sudarshan Paramsothy; Noa Krugliak Cleveland; Nada Zmeter; David T Rubin
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-12

4.  Position of the Canadian Association of Gastroenterology on subsequent entry biologics is challenged by biosimilar industry representatives.

Authors:  Miklos Sebeszta; Alex Kudrin
Journal:  Can J Gastroenterol Hepatol       Date:  2014-09

5.  Joint Canadian Association of Gastroenterology and Crohn's Colitis Canada Position Statement on Biosimilars for the Treatment of Inflammatory Bowel Disease.

Authors:  Paul Moayyedi; Eric I Benchimol; David Armstrong; Cathy Yuan; Aida Fernandes; Grigorios I Leontiadis
Journal:  J Can Assoc Gastroenterol       Date:  2019-11-08

Review 6.  Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review.

Authors:  Ross A McKinnon; Matthew Cook; Winston Liauw; Mona Marabani; Ian C Marschner; Nicolle H Packer; Johannes B Prins
Journal:  BioDrugs       Date:  2018-02       Impact factor: 5.807
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.